Skip to main content
Log in

Serum pepsinogen levels indicate the requirement of upper gastrointestinal endoscopy among Group A subjects of ABC classification: a multicenter study

  • Original Article—Alimentary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

ABC classification has been used to assess the risk for gastric cancer. The current problem of ABC classification is that Group A contains individuals with current and past H. pylori infection. The aims of this study were to assesse the proportion of current and past infection in Group A and to establish a criteria for the identification of subjects with past infection from Group A subjects with negative results of urea breath test (UBT) and/or stool antigen test.

Methods

201 subjects classified into Group A received UBT and/or stool antigen test, and also subsequent upper gastrointestinal endoscopy. The subjects were classified by the status of H. pylori infection defined by endoscopic findings. Levels of pepsinogen (PG) I, PG II and PG I/II ratio were compared between the groups, and receiver operating characteristic curves were constructed to extract the corresponding cutoff values.

Results

22 subjects were tested positive by UBT and/or stool antigen test. Endoscopic images of 157 out of 179 subjects were studied. 15 of the subjects were regarded to have past H. pylori infection. The optimal cut-off value of PG I and PG I/II ratio for the determination of past H. pylori infection were ≤ 31.2 ng/mL and ≤ 4.6, respectively.

Conclusions

Approximately 20% of Group A subjects have current or past H. pylori infection. Addition of UBT and/or stool antigen test can identify current but not past infection. Serum PG levels would be useful to identify subjects with past H. pylori infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels—“ABC method”. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:405–14.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Matsuo T, Ito M, Takata S, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415–9.

    Article  PubMed  Google Scholar 

  3. Kudo T, Kakizaki S, Sohara N, et al. Analysis of ABC (D) stratification for screening patients with gastric cancer. World J Gastroenterol. 2011;17:4793–8.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer. 2004;109:138–43.

    Article  PubMed  CAS  Google Scholar 

  5. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.

    Article  PubMed  CAS  Google Scholar 

  6. Miki K, Fujishiro M, Kodashima S, et al. Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc. 2009;21:78–81.

    Article  PubMed  Google Scholar 

  7. Yoshihara M, Hiyama T, Yoshida S, et al. Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case–control study. Scand J Gastroenterol. 2007;42:760–4.

    Article  PubMed  CAS  Google Scholar 

  8. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis. 2007;8:8–14.

    Article  PubMed  CAS  Google Scholar 

  9. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006;9:245–53.

    Article  PubMed  Google Scholar 

  10. Oishi Y, Kiyohara Y, Kubo M, et al. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol. 2006;163:629–37.

    Article  PubMed  Google Scholar 

  11. Dinis-Ribeiro M, Yamaki G, Miki K, et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen. 2004;11:141–7.

    Article  PubMed  CAS  Google Scholar 

  12. Urita Y, Hike K, Torii N, et al. Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis. Dig Dis Sci. 2004;49:795–801.

    Article  PubMed  CAS  Google Scholar 

  13. Kiso M, Yoshihara M, Ito M, et al. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study. Gastric Cancer. 2017;20:764–71.

    Article  PubMed  CAS  Google Scholar 

  14. Kishikawa H, Kimura K, Takarabe S, Kaida S, Nishida J. Helicobacter pylori antibody titer and gastric cancer screening. Dis Markers. 2015. https://doi.org/10.1155/2015/156719.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kishikawa H, Nishida J, Ichikawa H, et al. Fasting gastric pH of Japanese subjects stratified by IgG concentration against Helicobacter pylori and pepsinogen status. Helicobacter. 2011;16:427–33.

    Article  PubMed  CAS  Google Scholar 

  16. Kawai T, Miki K, Ichinose M, et al. Changes in evaluation of the pepsinogen test result following Helicobacter pylori eradication therapy in Japan. Inflammopharmacology. 2007;15:31–5.

    Article  PubMed  CAS  Google Scholar 

  17. Kawai T, Kawakami K, Kudo T, et al. A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication. Intern Med. 2002;41:780–3.

    Article  PubMed  CAS  Google Scholar 

  18. Ohara S, Kato M, Asaka M, et al. Studies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. J Gastroenterol. 1998;33:6–13.

    Article  PubMed  CAS  Google Scholar 

  19. Sato M, Shimoyama T, Takahashi R, et al. Characterization and usefulness of stool antigen tests using a monoclonal antibody to Helicobacter pylori catalase. J Gastroenterol Hepatol. 2012;27(Suppl 3):23–8.

    Article  PubMed  CAS  Google Scholar 

  20. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;3:87–97.

    Article  Google Scholar 

  21. Haruma K, Kato M, Inoue K, et al. Kyoto classification of gastritis. 1st ed. Tokyo: Nihon Medical Center; 2017.

  22. Kato T, Yagi N, Kamada T, et al. Study group for establishing endoscopic diagnosis of chronic gastritis diagnosis of Helicobacter pylori infection in gastric mucosa by endoscopic features: a multicenter prospective study. Dig Endosc. 2013;25:508–18.

    Article  PubMed  Google Scholar 

  23. Iino C, Shimoyama T, Oyama T, et al. Evaluation of the appropriate cut-off value for serological diagnosis of Helicobacter pylori infection by comparison with a stool antigen test. Hirosaki Med J. 2012;63:48–54.

    Google Scholar 

  24. Koizumi W, Tanabe S, Imaizumi H, et al. Effect of anti-Helicobacter pylori IgG antibody titer following eradication of Helicobacter pylori infection. Hepatogastroenterology. 2003;50:293–6.

    PubMed  Google Scholar 

  25. Marchildon P, Balaban DH, Sue M, et al. Usefulness of serological IgG antibody determinations for confirming eradication of Helicobacter pylori infection. Am J Gastroenterol. 1999;94:2105–8.

    Article  PubMed  CAS  Google Scholar 

  26. Yamaguchi Y, Nagata Y, Hiratsuka R, et al. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels—the ABC method. Digestion. 2016;93:13–8.

    Article  PubMed  CAS  Google Scholar 

  27. Terasawa T, Nishida H, Kato K, et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. PLoS One. 2014. https://doi.org/10.1371/journal.pone.0109783.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Boda T, Ito M, Yoshihara M, et al. Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm. Helicobacter. 2014;19:1–8.

    Article  PubMed  CAS  Google Scholar 

  29. Ono S, Kato M, Suzuki M, et al. Frequency of Helicobacter pylori -negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion. 2012;86:59–65.

    Article  PubMed  Google Scholar 

  30. Kakinoki R, Kushima R, Matsubara A, et al. Re-evaluation of histogenesis of gastric carcinomas: a comparative histopathological study between Helicobacter pylori-negative and H. pylori-positive cases. Dig Dis Sci. 2009;54:614–20.

    Article  PubMed  Google Scholar 

  31. Kato S, Matsukura N, Tsukada K, et al. Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci. 2007;98:790–4.

    Article  PubMed  CAS  Google Scholar 

  32. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005;54:764–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Shimoyama T. Stool antigen tests for the management of Helicobacter pylori infection. World J Gastroenterol. 2013;19:8188–91.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kishikawa H, Kimura K, Ito A, et al. Cutoff pepsinogen level for predicting unintendedly eradicated cases of Helicobacter pylori infection in subjects with seemingly normal pepsinogen levels. Digestion. 2017;95:229–36.

    Article  PubMed  CAS  Google Scholar 

  35. Yanaoka K, Oka M, Yoshimura N, et al. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int J Cancer. 2008;123:917–26.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge the members of The RINGO Study Group. The names of the RINGO study group are as follows: Chinda D, M.D, Ph.D. (author); Shimoyama T, M.D, Ph.D. (author); Sasaki Y, M.D., Ph.D. (author); Komai K, M.D., Ph.D. (author); Sawada Y, M.D., Ph.D. (author); Saito Y, M.D., Ph.D. (author); Chiba H, M.D., Ph.D. (author); Fukuda S, M.D., Ph.D. (author); Akiyama M, M.D., Ph.D.; Ebina T, M.D., Ph.D.; Fukushi G, M.D., Ph.D.; Fukushi M, M.D., Ph.D.; Ichinohe H, M.D., Ph.D.; Ishizawa M, M.D., Ph.D.; Ito J, M.D., Ph.D.; Iwamura H, M.D., Ph.D.; Iwane S, M.D., Ph.D.; Kawaguchi H, M.D., Ph.D.; Kawaguchi S, M.D., Ph.D.; Konuma Y, M.D., Ph.D.; Moriyama Y, M.D., Ph.D.; Nakajima M, M.D., Ph.D.; Nakasato F, M.D., Ph.D.; Nishiya D, M.D., Ph.D.; Okamoto K, M.D., Ph.D.; Soma Y, M.D., Ph.D.; Suzuki H, M.D., Ph.D.; Tomita T, M.D., Ph.D.; Tsushima K, M.D., Ph.D.; Wada T, M.D., Ph.D.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Tadashi Shimoyama.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

Additional information

The members of RINGO Study Group are listed in Acknowledgements.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chinda, D., Shimoyama, T., Mikami, T. et al. Serum pepsinogen levels indicate the requirement of upper gastrointestinal endoscopy among Group A subjects of ABC classification: a multicenter study. J Gastroenterol 53, 924–931 (2018). https://doi.org/10.1007/s00535-018-1431-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-018-1431-9

Keywords

Navigation